CXCR3 ligands in disease and therapy

Cytokine and Growth Factor Reviews

Volumn 26, Issue 3, 2015, Pages 311-327

  Van Raemdonck, Katrien ^a   Van den Steen, Philippe E ^a   Liekens, Sandra ^a   Van Damme, Jo ^a   Struyf, Sofie ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Chemokine; CXCR3; G protein coupled receptor

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL4 CHEMOKINE; CXCL4L1 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; LIGAND;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; ANGIOGENESIS; ATHEROSCLEROSIS; BINDING AFFINITY; CARCINOMA; DIABETES MELLITUS; DRUG TARGETING; GRAFT REJECTION; HEPATITIS; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKEMIA; LEUKOCYTE MIGRATION; LYMPHOMA; MALARIA; MOLECULAR PATHOLOGY; MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SARCOMA; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA; ANIMAL; DISEASES; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BIOMARKERS; CHEMOKINES; DISEASE; HUMANS; LIGANDS; RECEPTORS, CXCR3;

EID: 84929654337     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.11.009     Document Type: Review

References (299)

1. Rosenkilde M.M., Schwartz T.W. The chemokine system - a major regulator of angiogenesis in health and disease. APMIS 2004, 112:481-495.
2. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
3. Groom J.R., Luster A.D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011, 89:207-215.
4. Bachelerie F., Graham G.J., Locati M., Mantovani A., Murphy P.M., Nibbs R., et al. New nomenclature for atypical chemokine receptors. Nat Immunol 2014, 15:207-208.
5. Belperio J.A., Keane M.P., Arenberg D.A., Addison C.L., Ehlert J.E., Burdick M.D., et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000, 68:1-8.
6. Bosisio D., Salvi V., Gagliostro V., Sozzani S. Angiogenic and antiangiogenic chemokines. Chem Immunol Allergy 2014, 99:89-104.
7. Strieter R.M., Polverini P.J., Kunkel S.L., Arenberg D.A., Burdick M.D., Kasper J., et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995, 270:27348-27357.
8. Addison C.L., Daniel T.O., Burdick M.D., Liu H., Ehlert J.E., Xue Y.Y., et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 2000, 165:5269-5277.
9. Holmes W.E., Lee J., Kuang W.J., Rice G.C., Wood W.I. Structure and functional expression of a human interleukin-8 receptor. Science 1991, 253:1278-1280.
10. Dai X., Tan Y., Cai S., Xiong X., Wang L., Ye Q., et al. The role of CXCR7 on the adhesion, proliferation and angiogenesis of endothelial progenitor cells. J Cell Mol Med 2011, 15:1299-1309.
11. Lasagni L., Francalanci M., Annunziato F., Lazzeri E., Giannini S., Cosmi L., et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003, 197:1537-1549.
12. Cole K.E., Strick C.A., Paradis T.J., Ogborne K.T., Loetscher M., Gladue R.P., et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998, 187:2009-2021.
13. Loetscher M., Gerber B., Loetscher P., Jones S.A., Piali L., Clark-Lewis I., et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996, 184:963-969.
14. Ehlert J.E., Addison C.A., Burdick M.D., Kunkel S.L., Strieter R.M. Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol 2004, 173:6234-6240.
15. Struyf S., Salogni L., Burdick M.D., Vandercappellen J., Gouwy M., Noppen S., et al. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood 2011, 117:480-488.
16. Handel T.M., Johnson Z., Crown S.E., Lau E.K., Proudfoot A.E. Regulation of protein function by glycosaminoglycans - as exemplified by chemokines. Annu Rev Biochem 2005, 74:385-410.
17. Luster A.D., Greenberg S.M., Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 1995, 182:219-231.
18. Shute J. Glycosaminoglycan and chemokine/growth factor interactions. Handb Exp Pharmacol 2012, 307-324.
19. Kolset S.O., Mann D.M., Uhlin-Hansen L., Winberg J.O., Ruoslahti E. Serglycin-binding proteins in activated macrophages and platelets. J Leukoc Biol 1996, 59:545-554.
20. Pervushina O., Scheuerer B., Reiling N., Behnke L., Schroder J.M., Kasper B., et al. Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients. J Immunol 2004, 173:2060-2067.
21. Petersen F., Bock L., Flad H.D., Brandt E. A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J Immunol 1998, 161:4347-4355.
22. Scheuerer B., Ernst M., Durrbaum-Landmann I., Fleischer J., Grage-Griebenow E., Brandt E., et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000, 95:1158-1166.
23. Loetscher M., Loetscher P., Brass N., Meese E., Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 1998, 28:3696-3705.
24. Groom J.R., Luster A.D. CXCR3 in T cell function. Exp Cell Res 2011, 317:620-631.
25. Rabin R.L., Park M.K., Liao F., Swofford R., Stephany D., Farber J.M. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol 1999, 162:3840-3850.
26. Bonecchi R., Bianchi G., Bordignon P.P., D'Ambrosio D., Lang R., Borsatti A., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1T helper cells (Th1s) and Th2s. J Exp Med 1998, 187:129-134.
27. Szabo S.J., Kim S.T., Costa G.L., Zhang X., Fathman C.G., Glimcher L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000, 100:655-669.
28. Taqueti V.R., Grabie N., Colvin R., Pang H., Jarolim P., Luster A.D., et al. T-bet controls pathogenicity of CTLs in the heart by separable effects on migration and effector activity. J Immunol 2006, 177:5890-5901.
29. Koch M.A., Tucker-Heard G., Perdue N.R., Killebrew J.R., Urdahl K.B., Campbell D.J. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 2009, 10:595-602.
30. Garcia-Lopez M.A., Sanchez-Madrid F., Rodriguez-Frade J.M., Mellado M., Acevedo A., Garcia M.I., et al. CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells. Lab Invest 2001, 81:409-418.
31. Billottet C., Quemener C., Bikfalvi A.C.X.C.R3 a double-edged sword in tumor progression and angiogenesis. Biochim Biophys Acta 2013, 1836:287-295.
32. Colvin R.A., Campanella G.S., Sun J., Luster A.D. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 2004, 279:30219-30227.
33. Dagan-Berger M., Feniger-Barish R., Avniel S., Wald H., Galun E., Grabovsky V., et al. Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11. Blood 2006, 107:3821-3831.
34. Korniejewska A., McKnight A.J., Johnson Z., Watson M.L., Ward S.G. Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes. Immunology 2011, 132:503-515.
35. Xanthou G., Williams T.J., Pease J.E. Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. Eur J Immunol 2003, 33:2927-2936.
36. Colvin R.A., Campanella G.S., Manice L.A., Luster A.D. CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis. Mol Cell Biol 2006, 26:5838-5849.
37. Farber J.M. A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines. Proc Natl Acad Sci U S A 1990, 87:5238-5242.
38. Luster A.D., Ravetch J.V. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 1987, 166:1084-1097.
39. Loos T., Dekeyzer L., Struyf S., Schutyser E., Gijsbers K., Gouwy M., et al. TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis. Lab Invest 2006, 86:902-916.
40. Proost P., Vynckier A.K., Mahieu F., Put W., Grillet B., Struyf S., et al. Microbial Toll-like receptor ligands differentially regulate CXCL10/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN-gamma and provide a mechanism for enhanced synovial chemokine levels in septic arthritis. Eur J Immunol 2003, 33:3146-3153.
41. Proost P., Verpoest S., Van de Borne K., Schutyser E., Struyf S., Put W., et al. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids. J Leukoc Biol 2004, 75:777-784.
42. Kuo J.H., Chen Y.P., Liu J.S., Dubrac A., Quemener C., Prats H., et al. Alternative C-Terminal Helix Orientation Alters Chemokine Function: structure of the anti-angiogenic chemokine, CXCL4L1. J Biol Chem 2013, 288:13522-13533.
43. Struyf S., Burdick M.D., Proost P., Van Damme J., Strieter R.M. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res 2004, 95:855-857.
44. Lasagni L., Grepin R., Mazzinghi B., Lazzeri E., Meini C., Sagrinati C., et al. PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood 2007, 109:4127-4134.
45. Balestrieri M.L., Balestrieri A., Mancini F.P., Napoli C. Understanding the immunoangiostatic CXC chemokine network. Cardiovasc Res 2008, 78:250-256.
46. Vandercappellen J., Van Damme J., Struyf S. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev 2011, 22:1-18.
47. Vandercappellen J., Van Damme J., Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008, 267:226-244.
48. Folkman J., Merler E., Abernathy C., Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971, 133:275-288.
49. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
50. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer 2005, 5:735-743.
51. Prats A.C., Van den Berghe L., Rayssac A., Ainaoui N., Morfoisse F., Pujol F., et al. CXCL4L1-fibstatin cooperation inhibits tumor angiogenesis, lymphangiogenesis and metastasis. Microvasc Res 2013, 89:25-33.
52. Sica A. Role of tumour-associated macrophages in cancer-related inflammation. Exp Oncol 2010, 32:153-158.
53. Lakshmi Narendra B., Eshvendar R.K., Shantikumar S., Ramakrishna S. Immune system: a double-edged sword in cancer. Inflamm Res 2013, 62:823-834.
54. Verbeke H., Struyf S., Laureys G., Van Damme J. The expression and role of CXC chemokines in colorectal cancer. Cytokine Growth Factor Rev 2011, 22:345-358.
55. --CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine 2005, 29:105-117.
56. Suyama T., Furuya M., Nishiyama M., Kasuya Y., Kimura S., Ichikawa T., et al. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma. Cancer 2005, 103:258-267.
57. Goldberg-Bittman L., Neumark E., Sagi-Assif O., Azenshtein E., Meshel T., Witz I.P., et al. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol Lett 2004, 92:171-178.
58. Robledo M.M., Bartolome R.A., Longo N., Rodriguez-Frade J.M., Mellado M., Longo I., et al. Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001, 276:45098-45105.
59. Wu Q., Dhir R., Wells A. Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer 2012, 11.
60. Ma X., Norsworthy K., Kundu N., Rodgers W.H., Gimotty P.A., Goloubeva O., et al. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 2009, 8:490-498.
61. Kawada K., Hosogi H., Sonoshita M., Sakashita H., Manabe T., Shimahara Y., et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 2007, 26:4679-4688.
62. Monteagudo C., Martin J.M., Jorda E., Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J Clin Pathol 2007, 60:596-599.
63. Trentin L., Agostini C., Facco M., Piazza F., Perin A., Siviero M., et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J Clin Invest 1999, 104:115-121.
64. Jones D., Benjamin R.J., Shahsafaei A., Dorfman D.M. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000, 95:627-632.
65. Yan X.J., Dozmorov I., Li W., Yancopoulos S., Sison C., Centola M., et al. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood 2011, 118:5201-5210.
66. Ocana E., Delgado-Perez L., Campos-Caro A., Munoz J., Paz A., Franco R., et al. The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells. Haematologica 2007, 92:349-356.
67. Lee Y., Chittezhath M., Andre V., Zhao H., Poidinger M., Biondi A., et al. Protumoral role of monocytes in human B-cell precursor acute lymphoblastic leukemia: involvement of the chemokine CXCL10. Blood 2012, 119:227-237.
68. Khandany B.K., Hassanshahi G., Khorramdelazad H., Balali Z., Shamsizadeh A., Arababadi M.K., et al. Evaluation of circulating concentrations of CXCL1 (Gro-alpha), CXCL10 (IP-10) and CXCL12 (SDF-1) in ALL patients prior and post bone marrow transplantation. Pathol Res Pract 2012, 208:615-619.
69. Shi L.N., Zhang J., Wu P., Feng K., Li J., Xie Z.S., et al. Discovery and identification of potential biomarkers of pediatric Acute Lymphoblastic Leukemia. Proteome Sci 2009, 7.
70. Arthur D.C., Bloomfield C.D., Lindquist L.L., Nesbit M.E. Translocation 4-11 in acute lymphoblastic-leukemia - clinical characteristics and prognostic-significance. Blood 1982, 59:96-99.
71. Griffin C.A., Emanuel B.S., Larocco P., Schwartz E., Poncz M. Human platelet factor 4 gene is mapped to 4q12-q21. Cytogenet Cell Genet 1987, 45:67-69.
72. Bai J., He A.L., Zhang W.G., Huang C., Yang J., Yang Y., et al. Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling. Proteome Sci 2013, 11.
73. Kim J.Y., Song H.J., Lim H.J., Shin M.G., Kim J.S., Kim H.J., et al. Platelet factor-4 is an indicator of blood count recovery in acute myeloid leukemia patients in complete remission. Mol Cell Proteomics 2008, 7:431-441.
74. Olsnes A.M., Motorin D., Ryningen A., Zaritskey A.Y., Bruserud O. T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunol Immunother 2006, 55:830-840.
75. Wu B., Wang X., Ma W., Zheng W., Jiang L. Assay of OAZ1 mRNA levels in chronic myeloid leukemia combined with application of leukemia PCR array identified relevant gene changes affected by antizyme. Acta Haematol 2014, 131:141-147.
76. Kim H., Gillis L.C., Jarvis J.D., Yang S., Huang K., Der S., et al. Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events. BMC Cancer 2011, 11:528.
77. Teichmann M., Meyer B., Beck A., Niedobitek G. Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma. J Pathol 2005, 206:68-75.
78. Teruya-Feldstein J., Tosato G., Jaffe E.S. The role of chemokines in Hodgkin's disease. Leuk Lymphoma 2000, 38:363-371.
79. Ohshima K., Suefuji H., Karube K., Hamasaki M., Hatano B., Tutiya T., et al. Expression of chemokine receptor CXCR3 and its ligand, mig, in gastric and thyroid marginal zone lymphomas, Possible migration and autocrine mechanism. Leuk Lymphoma 2003, 44:329-336.
80. Suefuji H., Ohshima K., Karube K., Kawano R., Nabeshima K., Suzumiya J., et al. CXCR3-positive B cells found at elevated frequency in the peripheral blood of patients with MALT lymphoma are attracted by MIG and belong to the lymphoma clone. Int J Cancer 2005, 114:896-901.
81. Venetz D., Ponzoni M., Schiraldi M., Ferreri A.J., Bertoni F., Doglioni C., et al. Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells. Int J Cancer 2010, 127:2300-2312.
82. Haabeth O.A., Lorvik K.B., Hammarstrom C., Donaldson I.M., Haraldsen G., Bogen B., et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2011, 2:240.
83. Pellegrino A., Antonaci F., Russo F., Merchionne F., Ribatti D., Vacca A., et al. CXCR3-binding chemokines in multiple myeloma. Cancer Lett 2004, 207:221-227.
84. Giuliani N., Bonomini S., Romagnani P., Lazzaretti M., Morandi F., Colla S., et al. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 2006, 91:1489-1497.
85. Barash U., Zohar Y., Wildbaum G., Beider K., Nagler A., Karin N., et al. Heparanase enhances myeloma progression via CXCL10 downregulation. Leukemia 2014, 28:2178-2187.
86. Cheng S.H., Ng M.H.L., Lau K.M., Liu H.S.Y., Chan J.C.W., Hui A.B.Y., et al. 4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4. Blood 2007, 109:2089-2099.
87. Liang P., Cheng S.H., Cheng C.K., Lau K.M., Lin S.Y., Chow E.Y., et al. Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma. Haematologica 2013, 98:288-295.
88. Han Z.C., Lu M., Li J., Defard M., Boval B., Schlegel N., et al. Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents. Blood 1997, 89:2328-2335.
89. Antonelli A., Ferrari S.M., Giuggioli D., Ferrannini E., Ferri C., Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2014, 13:272-280.
90. Patel D.D., Zachariah J.P., Whichard L.P. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001, 98:39-45.
91. Ruschpler P., Lorenz P., Eichler W., Koczan D., Hanel C., Scholz R., et al. High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis. Arthritis Res Ther 2003, 5:R241-R252.
92. Erdem H., Pay S., Musabak U., Simsek I., Dinc A., Pekel A., et al. Synovial angiostatic non-ELR CXC chemokines in inflammatory arthritides: does CXCL4 designate chronicity of synovitis. Rheumatol Int 2007, 27:969-973.
93. Yamamoto T., Chikugo T., Tanaka Y. Elevated plasma levels of beta-thromboglobulin and platelet factor 4 in patients with rheumatic disorders and cutaneous vasculitis. Clin Rheumatol 2002, 21:501-504.
94. Pharoah D.S., Varsani H., Tatham R.W., Newton K.R., de Jager W., Prakken B.J., et al. Expression of the inflammatory chemokines CCL5, CCL3 and CXCL10 in juvenile idiopathic arthritis, and demonstration of CCL5 production by an atypical subset of CD8+ T cells. Arthritis Res Ther 2006, 8:R50.
95. Ueno A., Yamamura M., Iwahashi M., Okamoto A., Aita T., Ogawa N., et al. The production of CXCR3-agonistic chemokines by synovial fibroblasts from patients with rheumatoid arthritis. Rheumatol Int 2005, 25:361-367.
96. Badot V., Galant C., Nzeusseu Toukap A., Theate I., Maudoux A.L., Van den Eynde B.J., et al. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R57.
97. Singh U.P., Venkataraman C., Singh R., Lillard J.W. CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr Metab Immune Disord Drug Targets 2007, 7:111-123.
98. Yuan Y.H., ten H.T., The F.O., Slors J.F., van Deventer S.J., te Velde A.A. Chemokine receptor CXCR3 expression in inflammatory bowel disease. Inflamm Bowel Dis 2001, 7:281-286.
99. Simi M., Leardi S., Tebano M.T., Castelli M., Costantini F.M., Speranza V. Raised plasma concentrations of platelet factor 4 (Pf4) in Crohn's disease. Gut 1987, 28:336-338.
100. Vrij A.A., Rijken J., van Wersch J.W.J., Stockbrugger R.W. Platelet factor 4 and beta-thromboglobulin in inflammatory bowel disease and giant cell arteritis. Eur J Clin Invest 2000, 30:188-194.
101. Meuwis M.A., Fillet M., Geurts P., de Seny D., Lutteri L., Chapelle J.P., et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol 2007, 73:1422-1433.
102. Noguchi A., Watanabe K., Narumi S., Yamagami H., Fujiwara Y., Higuchi K., et al. The production of interferon-gamma-inducible protein 10 by granulocytes and monocytes is associated with ulcerative colitis disease activity. J Gastroenterol 2007, 42:947-956.
103. Uguccioni M., Gionchetti P., Robbiani D.F., Rizzello F., Peruzzo S., Campieri M., et al. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol 1999, 155:331-336.
104. Singh U.P., Singh S., Iqbal N., Weaver C.T., McGhee J.R., Lillard J.W. IFN-gamma-inducible chemokines enhance adaptive immunity and colitis. J Interferon Cytokine Res 2003, 23:591-600.
105. Papadakis K.A., Prehn J., Zhu D., Landers C., Gaiennie J., Fleshner P.R., et al. Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa. Inflamm Bowel Dis 2004, 10:778-788.
106. Schroepf S., Kappler R., Brand S., Prell C., Lohse P., Glas J., et al. Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis 2010, 16:1882-1890.
107. Lacher M., Kappler R., Berkholz S., Baurecht H., von Schweinitz D., Koletzko S. Association of a CXCL9 polymorphism with pediatric Crohn's disease. Biochem Biophys Res Commun 2007, 363:701-707.
108. Antonelli A., Ferrari S.M., Corrado A., Ferrannini E., Fallahi P.C.X.C.R3 CXCL10 and type 1 diabetes. Cytokine Growth Factor Rev 2014, 25:57-65.
109. Shimada A., Morimoto J., Kodama K., Suzuki R., Oikawa Y., Funae O., et al. Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 2001, 24:510-515.
110. Nicoletti F., Conget I., Di M.M., Di M.R., Mazzarino M.C., Bendtzen K., et al. Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2002, 45:1107-1110.
111. Antonelli A., Fallahi P., Ferrari S.M., Pupilli C., d'Annunzio G., Lorini R., et al. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. Diabet Med 2008, 25:1349-1353.
112. Rotondi M., Romagnani P., Brozzetti A., Santeusanio F., Serio M., Falorni A., et al. Reply to: Serum concentrations of the interferon-alpha-inducible chemokine IP-10/CXCL10 are augmented in both newly-diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2003, 46:1020-1021.
113. Hanifi-Moghaddam P., Kappler S., Seissler J., Muller-Scholze S., Martin S., Roep B.O., et al. Altered chemokine levels in individuals at risk of Type 1 diabetes mellitus. Diabet Med 2006, 23:156-163.
114. Rhode A., Pauza M.E., Barral A.M., Rodrigo E., Oldstone M.B., von Herrath M.G., et al. Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. J Immunol 2005, 175:3516-3524.
115. Roep B.O., Kleijwegt F.S., van Halteren A.G., Bonato V., Boggi U., Vendrame F., et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin Exp Immunol 2010, 159:338-343.
116. Devaraj S., Jialal I. Increased secretion of IP-10 from monocytes under hyperglycemia is via the TLR2 and TLR4 pathway. Cytokine 2009, 47:6-10.
117. Tanaka S., Nishida Y., Aida K., Maruyama T., Shimada A., Suzuki M., et al. Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes. Diabetes 2009, 58:2285-2291.
118. Sarkar S.A., Lee C.E., Victorino F., Nguyen T.T., Walters J.A., Burrack A., et al. Expression and regulation of chemokines in murine and human type 1 diabetes. Diabetes 2012, 61:436-446.
119. Uno S., Imagawa A., Saisho K., Okita K., Iwahashi H., Hanafusa T., et al. Expression of chemokines, CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islets of patients with recent-onset autoimmune type 1 diabetes. Endocr J 2010, 57:991-996.
120. Frigerio S., Junt T., Lu B., Gerard C., Zumsteg U., Hollander G.A., et al. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med 2002, 8:1414-1420.
121. Morimoto J., Yoneyama H., Shimada A., Shigihara T., Yamada S., Oikawa Y., et al. CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. J Immunol 2004, 173:7017-7024.
122. Schulthess F.T., Paroni F., Sauter N.S., Shu L., Ribaux P., Haataja L., et al. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metab 2009, 9:125-139.
123. Shimada A., Oikawa Y., Yamada Y., Okubo Y., Narumi S. The role of the CXCL10/CXCR3 system in type 1 diabetes. Rev Diabet Stud 2009, 6:81-84.
124. Ek I., Thunell S., Blomback M. Enhanced in vivo platelet activation in diabetes mellitus. Scand J Haematol 1982, 29:185-191.
125. Roy M.S., Podgor M.J., Rick M.E. Plasma fibrinopeptide A, beta-thromboglobulin, and platelet factor 4 in diabetic retinopathy. Invest Ophthalmol Vis Sci 1988, 29:856-860.
126. Nawaz M.I., Van Raemdonck K., Mohammad G., Kangave D., Van Damme J., Abu El-Asrar A.M., et al. Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy. Exp Eye Res 2013, 109:67-76.
127. Wakabayashi Y., Usui Y., Okunuki Y., Kezuka T., Takeuchi M., Goto H., et al. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina 2010, 30:339-344.
128. van Bon L., Affandi A.J., Broen J., Christmann R.B., Marijnissen R.J., Stawski L., et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014, 370:433-443.
129. Lima J., Fonollosa V., Fernandez-Cortijo J., Ordi J., Cuenca R., Khamashta M.A., et al. Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. J Rheumatol 1991, 18:1833-1836.
130. Maeda M., Kachi H., Mori S. Plasma levels of molecular markers of blood coagulation and fibrinolysis in progressive systemic sclerosis (PSS). J Dermatol Sci 1996, 11:223-227.
131. Kowal-Bielecka O., Kowal K., Lewszuk A., Bodzenta-Lukaszyk A., Walecki J., Sierakowski S. Beta thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Ann Rheum Dis 2005, 64:484-486.
132. Antonelli A., Ferri C., Fallahi P., Ferrari S.M., Giuggioli D., Colaci M., et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis - a longitudinal study. Rheumatology 2008, 47:45-49.
133. George P.M., Oliver E., Dorfmuller P., Dubois O.D., Reed D.M., Kirkby N.S., et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res 2014, 114:677-688.
134. Hasegawa M., Fujimoto M., Matsushita T., Hamaguchi Y., Takehara K., Sato S. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol 2011, 30:231-237.
135. Rabquer B.J., Tsou P.S., Hou Y., Thirunavukkarasu E., Haines G.K., Impens A.J., et al. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther 2011, 13:R18.
136. Fujii H., Shimada Y., Hasegawa M., Takehara K., Sato S. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci 2004, 35:43-51.
137. Sfriso P., Cozzi F., Oliviero F., Caso F., Cardarelli S., Facco M., et al. CXCL11 in bronchoalveolar lavage fluid and pulmonary function decline in systemic sclerosis. Clin Exp Rheumatol 2012, 30:S71-S75.
138. el-Sawy T., Fahmy N.M., Fairchild R.L. Chemokines: directing leukocyte infiltration into allografts. Curr Opin Immunol 2002, 14:562-568.
139. Romagnani P., Crescioli C. CXCL10: a candidate biomarker in transplantation. Clin Chim Acta 2012, 413:1364-1373.
140. Halloran P.F., Fairchild R.L. The puzzling role of CXCR3 and its ligands in organ allograft rejection. Am J Transplant 2008, 8:1578-1579.
141. Heidt S., San S.D., Shankar S., Mittal S., Muthusamy A.S., Friend P.J., et al. Peripheral blood sampling for the detection of allograft rejection: biomarker identification and validation. Transplantation 2011, 92:1-9.
142. Lazzeri E., Rotondi M., Mazzinghi B., Lasagni L., Buonamano A., Rosati A., et al. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation 2005, 79:1215-1220.
143. Rotondi M., Netti G.S., Lazzeri E., Stallone G., Bertoni E., Chiovato L., et al. High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients. Transpl Int 2010, 23:465-475.
144. Crescioli C., Buonamano A., Scolletta S., Sottili M., Francalanci M., Giomarelli P., et al. Predictive role of pretransplant serum CXCL10 for cardiac acute rejection. Transplantation 2009, 87:249-255.
145. Karason K., Jernas M., Hagg D.A., Svensson P.A. Evaluation of CXCL9 and CXCL10 as circulating biomarkers of human cardiac allograft rejection. BMC Cardiovasc Disord 2006, 6:29.
146. Kim S.C., Page E.K., Knechtle S.J. Urine proteomics in kidney transplantation. Transplant Rev (Orlando) 2014, 28:15-20.
147. Agostini C., Calabrese F., Rea F., Facco M., Tosoni A., Loy M., et al. Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 2001, 158:1703-1711.
148. Belperio J.A., Keane M.P., Burdick M.D., Lynch J.P., Zisman D.A., Xue Y.Y., et al. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. J Immunol 2003, 171:4844-4852.
149. Melter M., Exeni A., Reinders M.E., Fang J.C., McMahon G., Ganz P., et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001, 104:2558-2564.
150. Miura M., Morita K., Kobayashi H., Hamilton T.A., Burdick M.D., Strieter R.M., et al. Monokine induced by IFN-gamma is a dominant factor directing T cells into murine cardiac allografts during acute rejection. J Immunol 2001, 167:3494-3504.
151. Lo D.J., Weaver T.A., Kleiner D.E., Mannon R.B., Jacobson L.M., Becker B.N., et al. Chemokines and their receptors in human renal allotransplantation. Transplantation 2011, 91:70-77.
152. Goddard S., Williams A., Morland C., Qin S., Gladue R., Hubscher S.G., et al. Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants. Transplantation 2001, 72:1957-1967.
153. Asaoka T., Marubashi S., Kobayashi S., Hama N., Eguchi H., Takeda Y., et al. Intragraft transcriptome level of CXCL9 as biomarker of acute cellular rejection after liver transplantation. J Surg Res 2012, 178:1003-1014.
154. Hu H., Aizenstein B.D., Puchalski A., Burmania J.A., Hamawy M.M., Knechtle S.J. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 2004, 4:432-437.
155. Mitsuhashi N., Wu G.D., Zhu H., Kearns-Jonker M., Cramer D.V., Starnes V.A., et al. Rat chemokine CXCL11: structure, tissue distribution, function and expression in cardiac transplantation models. Mol Cell Biochem 2007, 296:1-9.
156. Zhao D.X., Hu Y., Miller G.G., Luster A.D., Mitchell R.N., Libby P. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol 2002, 169:1556-1560.
157. Shi G., Field D.J., Ko K.A., Ture S., Srivastava K., Levy S., et al. Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection. J Clin Invest 2014, 124:543-552.
158. Piper K.P., Horlock C., Curnow S.J., Arrazi J., Nicholls S., Mahendra P., et al. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. Blood 2007, 110:3827-3832.
159. Croudace J.E., Inman C.F., Abbotts B.E., Nagra S., Nunnick J., Mahendra P., et al. Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD. Blood 2012, 120:4246-4255.
160. Westekemper H., Meller S., Citak S., Schulte C., Steuhl K.P., Homey B., et al. Differential chemokine expression in chronic GVHD of the conjunctiva. Bone Marrow Transplant 2010, 45:1340-1346.
161. Kaplan K.L., Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981, 57:199-202.
162. Essien E.M., Ebhota M.I. Platelet hypersensitivity in acute malaria (Plasmodium falciparum) infection in man. Thromb Haemost 1981, 46:547-549.
163. Essien E.M., Ebhota M.I. Platelet secretory activities in acute malaria (Plasmodium falciparum) infection. Acta Haematol 1983, 70:183-188.
164. Lucchi N.W., Jain V., Wilson N.O., Singh N., Udhayakumar V., Stiles J.K. Potential serological biomarkers of cerebral malaria. Dis Markers 2011, 31:327-335.
165. Van den Steen P.E., Deroost K., Van Aelst I., Geurts N., Martens E., Struyf S., et al. CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-gamma-induced chemokines. Eur J Immunol 2008, 38:1082-1095.
166. Armah H.B., Wilson N.O., Sarfo B.Y., Powell M.D., Bond V.C., Anderson W., et al. Cerebrospinal fluid and serum biomarkers of cerebral malaria mortality in Ghanaian children. Malar J 2007, 6:147.
167. Wilson N.O., Jain V., Roberts C.E., Lucchi N., Joel P.K., Singh M.P., et al. CXCL4 and CXCL10 predict risk of fatal cerebral malaria. Dis Markers 2011, 30:39-49.
168. Wilson N., Driss A., Solomon W., Dickinson-Copeland C., Salifu H., Jain V., et al. CXCL10 gene promoter polymorphism -1447A>G correlates with plasma CXCL10 levels and is associated with male susceptibility to cerebral malaria. PLoS ONE 2013, 8:e81329.
169. Hansen D.S., Bernard N.J., Nie C.Q., Schofield L. NK cells stimulate recruitment of CXCR3+ T cells to the brain during Plasmodium berghei-mediated cerebral malaria. J Immunol 2007, 178:5779-5788.
170. Miu J., Mitchell A.J., Muller M., Carter S.L., Manders P.M., McQuillan J.A., et al. Chemokine gene expression during fatal murine cerebral malaria and protection due to CXCR3 deficiency. J Immunol 2008, 180:1217-1230.
171. Nie C.Q., Bernard N.J., Norman M.U., Amante F.H., Lundie R.J., Crabb B.S., et al. IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. PLoS Pathog 2009, 5:e1000369.
172. Srivastava K., Cockburn I.A., Swaim A., Thompson L.E., Tripathi A., Fletcher C.A., et al. Platelet factor 4 mediates inflammation in experimental cerebral malaria. Cell Host Microbe 2008, 4:179-187.
173. Srivastava K., Field D.J., Aggrey A., Yamakuchi M., Morrell C.N. Platelet factor 4 regulation of monocyte KLF4 in experimental cerebral malaria. PLoS ONE 2010, 5:e10413.
174. Lacerda-Queiroz N., Lima O.C., Carneiro C.M., Vilela M.C., Teixeira A.L., Teixeira-Carvalho A., et al. Plasmodium berghei NK65 induces cerebral leukocyte recruitment in vivo: an intravital microscopic study. Acta Trop 2011, 120:31-39.
175. Palomo J., Fauconnier M., Coquard L., Gilles M., Meme S., Szeremeta F., et al. Type I interferons contribute to experimental cerebral malaria development in response to sporozoite or blood-stage Plasmodium berghei ANKA. Eur J Immunol 2013, 43:2683-2695.
176. Campanella G.S., Tager A.M., El Khoury J.K., Thomas S.Y., Abrazinski T.A., Manice L.A., et al. Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proc Natl Acad Sci U S A 2008, 105:4814-4819.
177. Morrell C.N., Srivastava K., Swaim A., Lee M.T., Chen J., Nagineni C., et al. Beta interferon suppresses the development of experimental cerebral malaria. Infect Immun 2011, 79:1750-1758.
178. Love M.S., Millholland M.G., Mishra S., Kulkarni S., Freeman K.B., Pan W.X., et al. Platelet Factor 4 activity against P. falciparum and its translation to nonpeptidic mimics as antimalarials. Cell Host Microbe 2012, 12:815-823.
179. McMorran B.J., Burgio G., Foote S.J. New insights into the protective power of platelets in malaria infection. Commun Integr Biol 2013, 6. e23653-1-4.
180. Szabo M.C., Soo K.S., Zlotnik A., Schall T.J. Chemokine class differences in binding to the Duffy antigen-erythrocyte chemokine receptor. J Biol Chem 1995, 270:25348-25351.
181. McMorran B.J., Marshall V.M., de Graaf C., Drysdale K.E., Shabbar M., Smyth G.K., et al. Platelets kill intraerythrocytic malarial parasites and mediate survival to infection. Science 2009, 323:797-800.
182. McMorran B.J., Wieczorski L., Drysdale K.E., Chan J.A., Huang H.M., Smith C., et al. Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum. Science 2012, 338:1348-1351.
183. Murakami T., Yamamoto N. Roles of chemokines and chemokine receptors in HIV-1 infection. Int J Hematol 2000, 72:412-417.
184. Wu Y., Yoder A. Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog 2009, 5:e1000520.
185. Hatse S., Huskens D., Princen K., Vermeire K., Bridger G.J., De Clercq E., et al. Modest human immunodeficiency virus coreceptor function of CXCR3 is strongly enhanced by mimicking the CXCR4 ligand binding pocket in the CXCR3 receptor. J Virol 2007, 81:3632-3639.
186. Gray C.M., Hong H.A., Young K., Lewis D.A., Fallows D., Manca C., et al. Plasma interferon-gamma-inducible protein 10 can be used to predict viral load in HIV-1-infected individuals. J Acquir Immune Defic Syndr 2013, 63:e115-e116.
187. Sarkar S., Kalia V., Murphey-Corb M., Montelaro R.C., Reinhart T.A. Expression of IFN-gamma induced CXCR3 agonist chemokines and compartmentalization of CXCR3+ cells in the periphery and lymph nodes of rhesus macaques during simian immunodeficiency virus infection and acquired immunodeficiency syndrome. J Med Primatol 2003, 32:247-264.
188. Shacklett B.L., Cox C.A., Wilkens D.T., Karl K.R., Nilsson A., Nixon D.F., et al. Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. J Infect Dis 2004, 189:2202-2212.
189. Cinque P., Bestetti A., Marenzi R., Sala S., Gisslen M., Hagberg L., et al. Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol 2005, 168:154-163.
190. Kolb S.A., Sporer B., Lahrtz F., Koedel U., Pfister H.W., Fontana A. Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. J Neuroimmunol 1999, 93:172-181.
191. Izmailova E., Bertley F.M., Huang Q., Makori N., Miller C.J., Young R.A., et al. HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat Med 2003, 9:191-197.
192. Foley J.F., Yu C.R., Solow R., Yacobucci M., Peden K.W., Farber J.M. Roles for CXC chemokine ligands 10 and 11 in recruiting CD4+ T cells to HIV-1-infected monocyte-derived macrophages, dendritic cells, and lymph nodes. J Immunol 2005, 174:4892-4900.
193. Wetzel M.A., Steele A.D., Henderson E.E., Rogers T.J. The effect of X4 and R5 HIV-1 on C, C-C, and C-X-C chemokines during the early stages of infection in human PBMCs. Virology 2002, 292:6-15.
194. Asensio V.C., Maier J., Milner R., Boztug K., Kincaid C., Moulard M., et al. Interferon-independent, human immunodeficiency virus type 1 gp120-mediated induction of CXCL10/IP-10 gene expression by astrocytes in vivo and in vitro. J Virol 2001, 75:7067-7077.
195. Poluektova L., Moran T., Zelivyanskaya M., Swindells S., Gendelman H.E., Persidsky Y. The regulation of alpha chemokines during HIV-1 infection and leukocyte activation: relevance for HIV-1-associated dementia. J Neuroimmunol 2001, 120:112-128.
196. Mehla R., Bivalkar-Mehla S., Nagarkatti M., Chauhan A. Programming of neurotoxic cofactor CXCL-10 in HIV-1-associated dementia: abrogation of CXCL-10-induced neuro-glial toxicity in vitro by PKC activator. J Neuroinflammation 2012, 9:239.
197. van Marle G., Henry S., Todoruk T., Sullivan A., Silva C., Rourke S.B., et al. Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology 2004, 329:302-318.
198. Reinhart T.A. Chemokine induction by HIV-1: recruitment to the cause. Trends Immunol 2003, 24:351-353.
199. Lane B.R., King S.R., Bock P.J., Strieter R.M., Coffey M.J., Markovitz D.M. The C-X-C chemokine IP-10 stimulates HIV-1 replication. Virology 2003, 307:122-134.
200. Auerbach D.J., Lin Y., Miao H.Y., Cimbro R., DiFiore M.J., Gianolini M.E., et al. Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor. Proc Natl Acad Sci U S A 2012, 109:9569-9574.
201. Tsegaye T.S., Gnirss K., Rahe-Meyer N., Kiene M., Kramer-Kuhl A., Behrens G., et al. Platelet activation suppresses HIV-1 infection of T cells. Retrovirology 2013, 10:48.
202. Zeremski M., Markatou M., Brown Q.B., Dorante G., Cunningham-Rundles S., Talal A.H. Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr 2007, 45:262-268.
203. Qu J., Zhang Q., Li Y., Liu W., Chen L., Zhu Y., et al. The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10. BMC Immunol 2012, 13:15.
204. Berenguer J., Fernandez-Rodriguez A., Jimenez-Sousa M.A., Cosin J., Zarate P., Micheloud D., et al. High plasma CXCL10 levels are associated with HCV-genotype 1, and higher insulin resistance, fibrosis, and HIV viral load in HIV/HCV coinfected patients. Cytokine 2012, 57:25-29.
205. Roe B., Coughlan S., Hassan J., Grogan A., Farrell G., Norris S., et al. Elevated serum levels of interferon-gamma-inducible protein-10 in patients coinfected with hepatitis C virus and HIV. J Infect Dis 2007, 196:1053-1057.
206. Aabye M.G., Ruhwald M., Praygod G., Jeremiah K., Faurholt-Jepsen M., Faurholt-Jepsen D., et al. Potential of interferon-gamma-inducible protein 10 in improving tuberculosis diagnosis in HIV-infected patients. Eur Respir J 2010, 36:1488-1490.
207. Kabeer B.S., Sikhamani R., Raja A. Comparison of interferon gamma and interferon gamma-inducible protein-10 secretion in HIV-tuberculosis patients. AIDS 2010, 24:323-325.
208. Davenport G.C., Hittner J.B., Were T., Ong'echa J.M., Perkins D.J. Relationship between inflammatory mediator patterns and anemia in HIV-1 positive and exposed children with Plasmodium falciparum malaria. Am J Hematol 2012, 87:652-658.
209. Tang Y.Q., Yeaman M.R., Selsted M.E. Antimicrobial peptides from human platelets. Infect Immun 2002, 70:6524-6533.
210. Cole A.M., Ganz T., Liese A.M., Burdick M.D., Liu L., Strieter R.M. Cutting edge: IFN-inducible ELR-negative CXC chemokines display defensin-like antimicrobial activity. J Immunol 2001, 167:623-627.
211. Liu M.T., Armstrong D., Hamilton T.A., Lane T.E. Expression of Mig (monokine induced by interferon-gamma) is important in T lymphocyte recruitment and host defense following viral infection of the central nervous system. J Immunol 2001, 166:1790-1795.
212. Liu M.T., Chen B.P., Oertel P., Buchmeier M.J., Armstrong D., Hamilton T.A., et al. The T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease. J Immunol 2000, 165:2327-2330.
213. Fahey S., Dempsey E., Long A. The role of chemokines in acute and chronic hepatitis C infection. Cell Mol Immunol 2014, 11:25-40.
214. Larrubia J.R., Benito-Martinez S., Calvino M., Sanz-de-Villalobos E., Parra-Cid T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol 2008, 14:7149-7159.
215. Harvey C.E., Post J.J., Palladinetti P., Freeman A.J., Ffrench R.A., Kumar R.K., et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003, 74:360-369.
216. Nguyen N., de Esch C., Cameron B., Kumar R.K., Zekry A., Lloyd A.R. Positioning of leukocyte subsets in the portal and lobular compartments of hepatitis C virus-infected liver correlates with local chemokine expression. J Gastroenterol Hepatol 2014, 29:860-869.
217. Apolinario A., Majano P.L., Alvarez-Perez E., Saez A., Lozano C., Vargas J., et al. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease. Am J Gastroenterol 2002, 97:2861-2870.
218. Zeremski M., Dimova R., Brown Q., Jacobson I.M., Markatou M., Talal A.H. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis 2009, 200:1774-1780.
219. Wasmuth H.E., Lammert F., Zaldivar M.M., Weiskirchen R., Hellerbrand C., Scholten D., et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 2009, 137:309-319.
220. Sahin H., Borkham-Kamphorst E., do O.N.T., Berres M.L., Kaldenbach M., Schmitz P., et al. Proapoptotic effects of the chemokine, CXCL 10 are mediated by the noncognate receptor TLR4 in hepatocytes. Hepatology 2013, 57:797-805.
221. Helbig K.J., Ruszkiewicz A., Semendric L., Harley H.A., McColl S.R., Beard M.R. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology 2004, 39:1220-1229.
222. Zeremski M., Petrovic L.M., Chiriboga L., Brown Q.B., Yee H.T., Kinkhabwala M., et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008, 48:1440-1450.
223. Zaldivar M.M., Pauels K., von Hundelshausen P., Berres M.L., Schmitz P., Bornemann J., et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 2010, 51:1345-1353.
224. Dominguez M., Miquel R., Colmenero J., Moreno M., Garcia-Pagan J.C., Bosch J., et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 2009, 136:1639-1650.
225. Tacke F., Zimmermann H.W., Berres M.L., Trautwein C., Wasmuth H.E. Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases. Liver Int 2011, 31:840-849.
226. Mach F., Sauty A., Iarossi A.S., Sukhova G.K., Neote K., Libby P., et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999, 104:1041-1050.
227. Anger T., Pohle F.K., Kandler L., Barthel T., Ensminger S.M., Fischlein T., et al. VAP-1, Eotaxin3 and MIG as potential atherosclerotic triggers of severe calcified and stenotic human aortic valves: effects of statins. Exp Mol Pathol 2007, 83:435-442.
228. Ranjbaran H., Wang Y., Manes T.D., Yakimov A.O., Akhtar S., Kluger M.S., et al. Heparin displaces interferon-gamma-inducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells. Circulation 2006, 114:1293-1300.
229. Heller E.A., Liu E., Tager A.M., Yuan Q., Lin A.Y., Ahluwalia N., et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 2006, 113:2301-2312.
230. Sachais B.S., Turrentine T., Dawicki McKenna J.M., Rux A.H., Rader D., Kowalska M.A. Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE-/- mice. Thromb Haemost 2007, 98:1108-1113.
231. Koenen R.R., von Hundelshausen P., Nesmelova I.V., Zernecke A., Liehn E.A., Sarabi A., et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009, 15:97-103.
232. Aidoudi S., Bikfalvi A. Interaction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis. Thromb Haemost 2010, 104:941-948.
233. Gleissner C.A., Shaked I., Little K.M., Ley K. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol 2010, 184:4810-4818.
234. Nassar T., Sachais B.S., Akkawi S., Kowalska M.A., Bdeir K., Leitersdorf E., et al. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem 2003, 278:6187-6193.
235. Pitsilos S., Hunt J., Mohler E.R., Prabhakar A.M., Poncz M., Dawicki J., et al. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemostasis 2003, 90:1112-1120.
236. Ardigo D., Assimes T.L., Fortmann S.P., Go A.S., Hlatky M., Hytopoulos E., et al. Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. Physiol Genomics 2007, 31:402-409.
237. Heneka M.T., O'Banion M.K., Terwel D., Kummer M.P. Neuroinflammatory processes in Alzheimer's disease. J Neural Transm 2010, 117:919-947.
238. Xia M.Q., Hyman B.T. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol 1999, 5:32-41.
239. Xia M.Q., Bacskai B.J., Knowles R.B., Qin S.X., Hyman B.T. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol 2000, 108:227-235.
240. Sui Y., Stehno-Bittel L., Li S., Loganathan R., Dhillon N.K., Pinson D., et al. CXCL10-induced cell death in neurons: role of calcium dysregulation. Eur J Neurosci 2006, 23:957-964.
241. Lai W., Wu J., Zou X., Xie J., Zhang L., Zhao X., et al. Secretome analyses of Abeta(1-42) stimulated hippocampal astrocytes reveal that CXCL10 is involved in astrocyte migration. J Proteome Res 2013, 12:832-843.
242. Galimberti D., Schoonenboom N., Scheltens P., Fenoglio C., Venturelli E., Pijnenburg Y.A., et al. Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2006, 66:146-147.
243. Galimberti D., Schoonenboom N., Scheltens P., Fenoglio C., Bouwman F., Venturelli E., et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol 2006, 63:538-543.
244. Galimberti D., Venturelli E., Fenoglio C., Lovati C., Guidi I., Scalabrini D., et al. IP-10 serum levels are not increased in mild cognitive impairment and Alzheimer's disease. Eur J Neurol 2007, 14:e3-e4.
245. Duan R.S., Yang X., Chen Z.G., Lu M.O., Morris C., Winblad B., et al. Decreased fractalkine and increased IP-10 expression in aged brain of APP(swe) transgenic mice. Neurochem Res 2008, 33:1085-1089.
246. Hochstrasser T., Marksteiner J., Defrancesco M., Deisenhammer E.A., Kemmler G., Humpel C. Two blood monocytic biomarkers (CCL15 and p21) combined with the mini-mental state examination discriminate Alzheimer's disease patients from healthy subjects. Dement Geriatr Cogn Dis Extra 2011, 1:297-309.
247. Lee K.S., Chung J.H., Lee K.H., Shin M.J., Oh B.H., Hong C.H. Bioplex analysis of plasma cytokines in Alzheimer's disease and mild cognitive impairment. Immunol Lett 2008, 121:105-109.
248. Skovronsky D.M., Lee V.M., Pratico D. Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem 2001, 276:17036-17043.
249. Zhang W., Huang W., Jing F. Contribution of blood platelets to vascular pathology in Alzheimer's disease. J Blood Med 2013, 4:141-147.
250. Proudfoot A.E., Handel T.M., Johnson Z., Lau E.K., LiWang P., Clark-Lewis I., et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A 2003, 100:1885-1890.
251. Prechel M., Walenga J.M. Emphasis on the role of PF4 in the incidence, pathophysiology and treatment of heparin induced thrombocytopenia. Thromb J 2013, 11.
252. Rauova L., Hirsch J.D., Greene T.K., Zhai L., Hayes V.M., Kowalska M.A., et al. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood 2010, 116:5021-5031.
253. Cornelis J.J., Lang S.I., Stroh-Dege A.Y., Balboni G., Dinsart C., Rommelaere J. Cancer gene therapy through autonomous parvovirus-mediated gene transfer. Curr Gene Ther 2004, 4:249-261.
254. Hagedorn M., Zilberberg L., Lozano R.M., Cuevas P., Canron X., Redondo-Horcajo M., et al. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J 2001, 15:550-552.
255. Vandercappellen J., Liekens S., Bronckaers A., Noppen S., Ronsse I., Dillen C., et al. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo. Mol Cancer Res 2010, 8:322-334.
256. Wang P., Yang X., Xu W., Li K., Chu Y., Xiong S. Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy. Cancer Immunol Immunother 2010, 59:1715-1726.
257. van der Schaft D.W., Dings R.P., de Lussanet Q.G., van Eijk L.I., Nap A.W., Beets-Tan R.G., et al. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J 2002, 16:1991-1993.
258. Mayer L., Sandborn W.J., Stepanov Y., Geboes K., Hardi R., Yellin M., et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut 2014, 63:442-450.
259. Yellin M., Paliienko I., Balanescu A., Ter-Vartanian S., Tseluyko V., Xu L.A., et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2012, 64:1730-1739.
260. Nagy B., Miszti-Blasius K., Kerenyi A., Clemetson K.J., Kappelmayer J. Potential therapeutic targeting of platelet-mediated cellular interactions in atherosclerosis and inflammation. Curr Med Chem 2012, 19:518-531.
261. Lippi G., Favaloro E.J. Recombinant platelet factor 4: a therapeutic, anti-neoplastic chimera. Semin Thromb Hemost 2010, 36:558-569.
262. Lazzeri E., Romagnani P. CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord 2005, 5:109-118.
263. Christen U. Chemokines as drug targets in type 1 diabetes. Endocr Metab Immune Disord Drug Targets 2007, 7:7-12.
264. De Sutter J., van de Veire N.R., Struyf S., Philippe J., De Buyzere M., Van Damme J. PF-4var/CXCL4L1 predicts outcome in stable coronary artery disease patients with preserved left ventricular function. PLoS ONE 2012, 7:e31343.
265. Meuwis M.A., Fillet M., Lutteri L., Maree R., Geurts P., de Seny D., et al. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clin Biochem 2008, 41:960-967.
266. Trocme C., Marotte H., Baillet A., Pallot-Prades B., Garin J., Grange L., et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1328-1333.
267. Romero A.I., Lagging M., Westin J., Dhillon A.P., Dustin L.B., Pawlotsky J.M., et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006, 194:895-903.
268. Falconer K., Askarieh G., Weis N., Hellstrand K., Alaeus A., Lagging M. IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV. Scand J Infect Dis 2010, 42:896-901.
269. Casrouge A., Decalf J., Ahloulay M., Lababidi C., Mansour H., Vallet-Pichard A., et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011, 121:308-317.
270. Ragab D., Laird M., Duffy D., Casrouge A., Mamdouh R., Abass A., et al. CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients. Cytokine 2013, 63:105-112.
271. Proost P., Schutyser E., Menten P., Struyf S., Wuyts A., Opdenakker G., et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001, 98:3554-3561.
272. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z., et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006, 203:2201-2213.
273. Chaudhuri A., Zbrzezna V., Polyakova J., Pogo A.O., Hesselgesser J., Horuk R. Expression of the Duffy antigen in K562 cells. Evidence that it is the human erythrocyte chemokine receptor. J Biol Chem 1994, 269:7835-7838.
274. Gardner L., Patterson A.M., Ashton B.A., Stone M.A., Middleton J. The human Duffy antigen binds selected inflammatory but not homeostatic chemokines. Biochem Biophys Res Commun 2004, 321:306-312.
275. Wu Z., Han X., Yan J., Pan Y., Gong J., Di J., et al. The prognostic significance of chemokine receptor CXCR3 expression in colorectal carcinoma. Biomed Pharmacother 2012, 66:373-377.
276. Gupta S.K., Hassel T., Singh J.P. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci U S A 1995, 92:7799-7803.
277. Zipfel P.F., Bialonski A., Skerka C. Induction of members of the IL-8/NAP-1 gene family in human T lymphocytes is suppressed by cyclosporin A. Biochem Biophys Res Commun 1991, 181:179-183.
278. Struyf S., Burdick M.D., Peeters E., Van den Broeck K., Dillen C., Proost P., et al. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res 2007, 67:5940-5948.
279. Lu X.L., Jiang X.B., Liu R.E., Zhang S.M. The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10. Vaccine 2008, 26:5352-5357.
280. Keyser J., Schultz J., Ladell K., Elzaouk L., Heinzerling L., Pavlovic J., et al. IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency. Exp Dermatol 2004, 13:380-390.
281. Sharpe R.J., Byers H.R., Scott C.F., Bauer S.I., Maione T.E. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 1990, 82:848-853.
282. Kolber D.L., Knisely T.L., Maione T.E. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 1995, 87:304-309.
283. Arenberg D.A., White E.S., Burdick M.D., Strom S.R., Strieter R.M. Improved survival in tumor-bearing SCID mice treated with interferon-gamma-inducible protein 10 (IP-10/CXCL10). Cancer Immunol Immunother 2001, 50:533-538.
284. Li G., Tian L., Hou J.M., Ding Z.Y., He Q.M., Feng P., et al. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors. Clin Cancer Res 2005, 11:4217-4224.
285. Wang Y.Q., Wada A., Ugai S., Tagawa M. Expression of the Mig (CXCL9) gene in murine lung carcinoma cells generated angiogenesis-independent antitumor effects. Oncol Rep 2003, 10:909-913.
286. Zhang R., Tian L., Chen L.J., Xiao F., Hou J.M., Zhao X., et al. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma. Gene Ther 2006, 13:1263-1271.
287. Ruehlmann J.M., Xiang R., Niethammer A.G., Ba Y., Pertl U., Dolman C.S., et al. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res 2001, 61:8498-8503.
288. Pan J., Burdick M.D., Belperio J.A., Xue Y.Y., Gerard C., Sharma S., et al. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol 2006, 176:1456-1464.
289. Walser T.C., Ma X., Kundu N., Dorsey R., Goloubeva O., Fulton A.M. Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model. J Immunother 2007, 30:490-498.
290. Hampl M., Tanaka T., Albert P.S., Lee J., Ferrari N., Fine H.A. Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites. Hum Gene Ther 2001, 12:1713-1729.
291. Yang F., Gou M., Deng H., Yi T., Zhong Q., Wei Y., et al. Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels. Oncol Rep 2012, 28:668-676.
292. Jiang X.B., Lu X.L., Hu P., Liu R.E. Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma. Vaccine 2009, 27:6210-6216.
293. Liu T.C., Zhang T., Fukuhara H., Kuroda T., Todo T., Martuza R.L., et al. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther 2006, 14:789-797.
294. Enderlin M., Kleinmann E.V., Struyf S., Buracchi C., Vecchi A., Kinscherf R., et al. TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther 2009, 16:149-160.
295. Antoszczyk S., Spyra M., Mautner V.F., Kurtz A., Stemmer-Rachamimov A.O., Martuza R.L., et al. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro Oncol 2014, 16:1066.
296. Chen P., Yang L.L., Yang H.S., Wang Y.S., Li G., Wu Y., et al. Synergistic antitumor effect of CXCL10 with hyperthermia. J Cancer Res Clin Oncol 2008, 134:679-687.
297. Giese N.A., Raykov Z., DeMartino L., Vecchi A., Sozzani S., Dinsart C., et al. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther 2002, 9:432-442.
298. Sgadari C., Farber J.M., Angiolillo A.L., Liao F., Teruya-Feldstein J., Burd P.R., et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997, 89:2635-2643.
299. Hensbergen P.J., Wijnands P.G., Schreurs M.W., Scheper R.J., Willemze R., Tensen C.P. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. J Immunother 2005, 28:343-351.